Your selection
NoneFilter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
July 19, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs, including LEQEMBI; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
BIOGEN TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS JULY 25, 2023
July 10, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
July 6, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
June 30, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Announces 2023 Annual Shareholder Meeting Preliminary Results
June 26, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … of, and expectations for, our commercial business, pipeline programs and clinical development programs. These … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Announces Changes to Its Board of Directors
June 12, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … of, and expectations for, our commercial business, pipeline programs and clinical development programs. These … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
June 9, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental Biologics License Application for the Potential Traditional Approval of LEQEMBI in Early Alzheimer’s Disease
June 9, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN SOUTH KOREA
June 7, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Withdrawal from the Jefferies Healthcare Conference
June 6, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
